MANKIND PHARMA
|
MANKIND PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 47.75 | 32.00 | 35.78 | 31.59 | 25.72 |
| CEPS(Rs) | 58.41 | 40.83 | 40.43 | 35.25 | 28.84 |
| DPS(Rs) | - | - | - | - | 3.10 |
| Book NAV/Share(Rs) | 233.15 | 185.61 | 153.65 | 117.88 | 87.00 |
| Tax Rate(%) | 19.07 | 21.63 | 26.42 | 23.56 | 26.54 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 23.59 | 20.89 | 24.66 | 25.50 | 23.68 |
| EBIT Margin(%) | 22.64 | 18.86 | 25.21 | 26.49 | 23.95 |
| Pre Tax Margin(%) | 22.32 | 18.35 | 24.47 | 26.16 | 23.57 |
| PAT Margin (%) | 18.06 | 14.38 | 18.00 | 20.00 | 17.31 |
| Cash Profit Margin (%) | 21.76 | 17.96 | 20.07 | 21.84 | 18.94 |
| Performance Ratios | |||||
| ROA(%) | 18.01 | 13.94 | 18.83 | 22.79 | 23.19 |
| ROE(%) | 23.15 | 19.27 | 26.72 | 31.51 | 33.48 |
| ROCE(%) | 28.38 | 23.49 | 33.96 | 39.97 | 43.57 |
| Asset Turnover(x) | 1.00 | 0.97 | 1.05 | 1.14 | 1.34 |
| Sales/Fixed Asset(x) | 1.93 | 1.92 | 2.52 | 3.12 | 3.33 |
| Working Capital/Sales(x) | 2.42 | 3.70 | 4.53 | 2.56 | 3.89 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.52 | 0.52 | 0.40 | 0.32 | 0.30 |
| Receivable days | 24.18 | 19.33 | 16.25 | 24.32 | 22.48 |
| Inventory Days | 51.80 | 65.31 | 66.57 | 58.78 | 51.46 |
| Payable days | 120.04 | 130.57 | 131.38 | 144.73 | 127.01 |
| Valuation Parameters | |||||
| PER(x) | 48.11 | - | - | - | - |
| PCE(x) | 39.33 | - | - | - | - |
| Price/Book(x) | 9.85 | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 8.81 | -0.03 | 0.06 | -0.07 | -0.04 |
| EV/Core EBITDA(x) | 32.31 | -0.12 | 0.23 | -0.23 | -0.16 |
| EV/EBIT(x) | 37.39 | -0.15 | 0.25 | -0.25 | -0.17 |
| EV/CE(x) | 9.52 | -0.03 | 0.06 | -0.07 | -0.05 |
| M Cap / Sales | 8.90 | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 18.12 | 12.44 | 25.22 | 5.83 | 17.91 |
| Core EBITDA Growth(%) | 38.76 | -7.14 | 20.14 | 17.54 | 58.34 |
| EBIT Growth(%) | 41.78 | -15.60 | 18.78 | 17.23 | 59.00 |
| PAT Growth(%) | 48.26 | -9.86 | 12.37 | 22.43 | 73.00 |
| EPS Growth(%) | 49.23 | -10.58 | 13.28 | 22.81 | 78.11 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.02 | 0.14 | 0.05 | 0.04 |
| Current Ratio(x) | 3.10 | 2.32 | 1.68 | 2.87 | 2.25 |
| Quick Ratio(x) | 2.36 | 1.52 | 1.01 | 2.05 | 1.54 |
| Interest Cover(x) | 69.46 | 37.52 | 34.02 | 80.96 | 62.87 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹106,515.5 Cr | -2.8% | -0.7% | 52% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,604.0 Cr | 0.1% | -4% | 52.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹157,639.0 Cr | 0.7% | -0% | 70.9% | Stock Analytics | |
| CIPLA | ₹128,549.0 Cr | 0.5% | -1.7% | 29.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,956.0 Cr | 1.1% | -2.6% | 19.2% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,468.9 Cr | -3.6% | -8.4% | 62.9% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -2.8% |
-0.7% |
52% |
| SENSEX | -0.3% |
-2.4% |
22.4% |
You may also like the below Video Courses
